rolipram selective inhibitor discovered developed schering ag potential antidepressant drug early served prototype molecule several companies drug discovery development rolipram discontinued clinical trials showed therapeutic window narrow could dosed high enough levels effective without causing significant gastrointestinal side rolipram several activities make continuing focus research etiology many neurodegenerative diseases involves misfolded clumped proteins accumulate brain cells mechanism dispose proteins called proteasome however alzheimers disease conditions activity proteasomes impaired leading buildup toxic aggregates research mice suggests rolipram ability ramp activity proteasomes reduce burden aggregates preliminary evidence suggests improve spatial memory mice engineered aggregate rolipram continues used research wellcharacterized used studies understand whether inhibition could useful autoimmune alzheimers cognitive spinal cord respiratory diseases like asthma httpsenwikipediaorgwikirolipram